Is BPC-157 legal to buy in the US?

Is BPC-157 legal? The short answer, as of November 12, 2026

The answer to “is BPC-157 legal” has four parts, and only the last concerns a buyer of research material. First, BPC-157 is not approved by the FDA, so it cannot be sold or marketed as a drug. Second, it is not a controlled substance: it does not appear in the federal drug schedules. Third, since October 30, 2026 HHS has said it does not intend to act against state-licensed pharmacies and physicians compounding it for patients, under a draft interim policy that approves nothing. Fourth, research-grade BPC-157 is sold to laboratories for research use only, a channel the HHS policy does not cover.

This page is not legal advice; it is a dated summary of what the FDA, HHS, the eCFR and USADA say. Prices and vendors are on our buy BPC-157 page.

See research-grade BPC-157 at Astral →

Is BPC-157 FDA approved?

No. As of November 12, 2026, BPC-157 is not FDA-approved for any use. USADA’s page states that it “is not approved for human clinical use by the U.S. Food and Drug Administration (FDA) or any other global health authority.” A 2026 review in Pharmaceutics puts the development picture in one line: “no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial.” Astral’s product page says the same: as of November 2026 it has no FDA approval.

Two things happened in 2026 that get mistaken for approval. Neither is one; both concern compounding.

What is BPC-157’s compounding status with the FDA?

Pharmacies compounding under section 503A of the Federal Food, Drug, and Cosmetic Act may use a bulk drug substance that appears on an FDA list developed through rulemaking, and while that list is built the FDA sorts nominated substances into interim categories. BPC-157 was nominated and placed in Category 2, the category for substances the agency says may present significant safety risks; law-firm summaries date that placement to September 2023 and the removal to April 15, 2026, and the FDA’s page gives no date for either.

The FDA’s Category 2 page, current as of April 22, 2026, now lists BPC-157 under the heading “Bulk drug substances nominated but withdrawn”, introduced with the sentence: “This list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators.” The entry still carries the agency’s concern that “Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration.” TB-500 sits on the same withdrawn list. Withdrawal does not place a substance on the 503A list, and the same summaries note it does not make one eligible for compounding.

What did the July 23, 2026 advisory committee vote decide?

The FDA took BPC-157 to its advisory committee regardless. The meeting notice in the Federal Register of April 16, 2026 (document 2026-07361, docket FDA-2025-N-6895) states that “On July 23, 2026, the Committee will discuss the following bulk drug substances”, listing “BPC-157-related bulk drug substances (BPC-157 (free base)/BPC-157 acetate)” for the use “Ulcerative colitis (UC)” and “TB-500-related bulk drug substances (TB-500 (free base)/TB-500 acetate)” for “Wound healing”. The FDA’s briefing document proposed that neither form be included on the 503A list.

The committee disagreed, narrowly. According to the law firm McDermott’s account, the vote on BPC-157 was eight yes, six no and one abstention to recommend inclusion, with the same tally for TB-500, and “In each instance, FDA scientists recommended against inclusion of the peptides.” The FDA’s meeting page notes that committee recommendations are non-binding and, as of November 12, 2026, posts no vote record. Listing requires rulemaking, which the same account says “could occur in 2027 or extend into a multi-year process.”

What does the October 30, 2026 HHS notice change?

On October 30, 2026 HHS, not the FDA, published a notice in the Federal Register (document 2026-22192, docket HHS-OASH-2026-0496) announcing a draft interim enforcement-discretion policy. Its operative sentence: “HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A” while the 503A list is developed through rulemaking. The notice says the policy “does not establish any rights for any person and is not binding on HHS or the public”, that “Written comments can be submitted until 2 weeks after date of publication in the Federal Register”, and that HHS “may revisit application of this interim policy (in whole or in part) if, among other things, a safety signal or product quality issue arises”.

The Federal Register text refers to Appendix A without listing it. According to Holland & Knight’s November 4, 2026 summary, the six peptides are BPC-157 acetate, TB-500 acetate, epitalon acetate, KPV acetate, MOTS-c acetate and Semax, each limited to named routes, and one condition is that a compounded product “contains only a single API listed in Appendix A”, which excludes a BPC-157 and TB-500 blend. The same summary says the policy aims to discourage the use of peptides labeled research use only and supplied by foreign manufacturers, and does not extend to research-use-only material.

What it does not do matters as much. It does not approve BPC-157: the notice itself states that “Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed.” It does not add BPC-157 to the 503A list. It is a draft, open for comment, and revocable. And it covers licensed compounders, not laboratories buying a reagent or vendors selling one.

Is BPC-157 a controlled substance?

No. BPC-157 is not listed as a controlled substance. A search of the Electronic Code of Federal Regulations on November 12, 2026 for “BPC-157” returns no results in any title, including 21 CFR part 1308, where the DEA’s schedules live. That is an absence in the regulations rather than a DEA statement, and scheduling can change, but as of November 12, 2026 BPC-157 is not governed by the Controlled Substances Act.

Is BPC-157 banned in sports?

Yes, at all times. The World Anti-Doping Agency’s Prohibited List places BPC-157 in class S0, non-approved substances. USADA’s page on BPC-157 states that it “is prohibited under the World Anti-Doping Agency (WADA) Prohibited List in the category of S0 Non-Approved Substances.” TB-500 falls under a different class: USADA’s advisory on the 2027 list lists “BPC-157 (Prohibited under S0)” and “TB-500 (Prohibited under S2)”, and notes that on the 2027 list, effective January 1, 2027, “peptides” in general are now named in S0. We have not verified the NCAA’s list against BPC-157 by name and make no claim about it.

Can I buy BPC-157 in the US?

A laboratory can. Research suppliers in the United States, including Astral, sell BPC-157 as a lyophilized powder for laboratory research only: a sale of a research chemical to a lab, with terms that exclude human use and no prescription, since no approved product exists to prescribe.

A patient cannot buy it as a medicine. Since October 30, 2026 the HHS interim policy says HHS does not intend to act against a licensed physician or 503A pharmacy compounding BPC-157 for an individual patient on a prescription, and the notice is explicit that such a product remains unapproved. Trials are the other route: ClinicalTrials.gov lists a phase 2 study, NCT07437547, recruiting as of November 12, 2026.

What does research use only mean for a buyer?

It means the product is a reagent, not a medicine. A research-use-only peptide has not been manufactured under the standards that apply to drugs, has not been reviewed by any regulator for safety in people, and is sold as a lyophilized vial on the condition that it will be used in a laboratory. Astral’s product page says it outright: it sells BPC-157 as a research chemical for laboratory use, not as a medicine or a supplement.

It does not mean the label settles anything on its own. In a February 26, 2025 warning letter to an online peptide seller (naming other peptides, not BPC-157), the agency wrote that “research use only” statements on labeling and the website did not change its conclusion that the products were unapproved new drugs, because the site described uses in people. A vendor whose BPC-157 page describes effects in people is advertising a drug; one that names the molecule and sells it for research without health claims is doing what a research supplier should.

Where do research buyers get BPC-157?

From research suppliers that sell it as a reagent. Among the vendors we compare, Astral is our pick: it synthesizes and manufactures its peptides in the United States, ships from its own New York inventory, sells BPC-157 as a 10 mg vial at $47.99, and keeps its product page to research-use language, including a plain statement that the compound has no FDA approval. On those points it is in a class of its own. It also stocks Wolverine (Astral’s BPC-157 + TB-500 blend); our BPC-157 vs Wolverine page notes how the HHS policy’s single-ingredient condition bears on blends.

Buy BPC-157 for research at Astral →